论文部分内容阅读
目的:探讨炎症性肠病患者采用益生菌联合美沙拉嗪治疗的临床效果。方法:随机选取我院自2015年9月-2016年9月间入院治疗的84例炎症性肠炎患者,将其按照随机数法分为两组,对照组(42例)患者采用美沙拉嗪治疗,观察组(42例)患者采用益生菌与美沙拉嗪治疗,观察两组患者的临床效果及不良反应情况。结果:经过治疗,观察组患者的临床有效率为95.3%,观察组不良反应(ADR)发生率为4.8%,两项指标均显著优于对照组(80.9%.21.3%),数据差异显著(P<0.05)。结论:在炎症性肠病患者的临床治疗中采用益生菌联合美沙拉嗪治疗,安全性高疗效显著,值得推广。
Objective: To investigate the clinical effect of using probiotics combined with mesalazine in patients with inflammatory bowel disease. Methods: A total of 84 inflammatory bowel disease patients admitted to our hospital from September 2015 to September 2016 were randomly selected and divided into two groups according to the random number method. Patients in the control group (42 patients) were treated with mesalazine , And the observation group (42 cases) were treated with probiotics and mesalazine. The clinical effects and adverse reactions of the two groups were observed. Results: After treatment, the clinical effective rate was 95.3% in the observation group and 4.8% in the observation group. The two indexes were significantly better than those in the control group (80.9% and 21.3%, respectively) P <0.05). Conclusion: Probiotics combined with mesalazine in the clinical treatment of patients with inflammatory bowel disease is safe and effective, which is worthy of promotion.